Decreased Lung Metastasis in Triple Negative Breast Cancer Following Locally Delivered Supratherapeutic Paclitaxel-Loaded Polyglycerol Carbonate Nanoparticle Therapy
Year: 2024
Type: article
Abstract: Breast cancer is among the most prevalent malignancies, accounting for 685,000 deaths worldwide in 2020, largely due to its high metastatic potential. Depending on the stage and tumor characteristics, treatment involves surgery, chemotherapy, targeted biologics, and/or radiation therapy. However, current treatments are insufficient for treating or preventing metastatic disease. Herein, we describe supratherapeutic paclitaxel-loaded nanoparticles (81 wt % paclitaxel) to treat the primary tumor and reduce the risk of subsequent metastatic lesions in the lungs. Primary tumor volume and lung metastasis are reduced by day 30, compared to the paclitaxel clinical standard treatment. The ultrahigh levels of paclitaxel afford an immunotherapeutic effect, increasing natural killer cell activation and decreasing NETosis in the lung, which limits the formation of metastatic lesions.
Source: Biomacromolecules
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: green
Funders: Thoracic Surgery Foundation, Boston Area Diabetes Endocrinology Research Center, National Institutes of Health, Office of the Director, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Biomedical Imaging and Bioengineering
Awards: Boston Area Diabetes Endocrinology Research Center, G1589144027, G2118519186, A Zeiss LSM800 confocal microscope with Airyscan, Development of a Surgical Drug Delivery System for Enhancement of CAR T Cell Activity, Synthetic Biology and Biotechnology (SB2) Predoctoral Training Program, G4883012012, OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA, G5697257965, TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE, G9000011862, G9000146438, Boston Area Diabetes and Endocrinology Research Center (BADERC), Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital, Translational Research in Biomaterials
OpenAlex ID: W4392090876